Synthesis and muscarinic activity of novel aniline derivatives with a 1- azabicyclo[3.3.0]octane moiety

Chemical and Pharmaceutical Bulletin

Volumn 47, Issue 1, 1999, Pages 28-36

  Suzuki, Tomoo ^a   Oka, Mitsuru ^a   Maeda, Kouji ^a   Furusawa, Kenichi ^a   Uesaka, Hiroshi ^a   Kataoka, Tadashi ^b  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1 azabicyclo 3.3.1 nonane; 1 azabicyclo 3.3.0 octane; Alzheimer's disease; Muscarinic receptor binding affinity; SK 946

Indexed keywords

ANILINE DERIVATIVE; BICYCLO[3.3.0]OCTANE DERIVATIVE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; N METHANESULFONYL 3 [[1 [N (2 NAPHTHOYL)VALYL]PROLYL]AMINO] 4 OXOBUTANAMIDE; N [2 (1 AZABICYCLO[3.3.0]OCTAN 5 YL)ETHYL] 2 NITROANILINE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; DEMENTIA; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; RAT; RECEPTOR AFFINITY;

EID: 0033034964     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.47.28     Document Type: Article

References (17)

1. Suzuki T., Oka M., Maeda K., Furusawa K., Mitani T., Kataoka T., Chem. Pharm. Bull., 45, 1218-1220 (1997).
2. Ejner K. M., Berith B., Drug Fut., 20, 37-54 (1995).
3. Iversen L. L., Mortishire-Smith R. J., Pollack S. J., Shearman M. S., Biochem. J., 311, 1-16 (1995).
4. Bartus R. T., Dean R. L., Beer B., Lippa A. S., Science, 217, 408-417 (1982).
5. Tsukamoto S., Fujii M., Yasunaga T., Matsuda K., Wanibuchi F., Hidaka A., Furuya T., Tamura T., Chem. Pharm. Bull. 43, 842-852 (1995); Wanibuchi F., Konishi T., Harada M., Terai M., Hidaka K., Tamura T., Tsukamoto S., Usuda S., European J. Pharmacol., 187, 479-486 (1990).
6. Tsukamoto S., Fujii M., Yasunaga T., Matsuda K., Wanibuchi F., Hidaka A., Furuya T., Tamura T., Chem. Pharm. Bull. 43, 842-852 (1995); Wanibuchi F., Konishi T., Harada M., Terai M., Hidaka K., Tamura T., Tsukamoto S., Usuda S., European J. Pharmacol., 187, 479-486 (1990).
7. Wermuth C. G., Bourguignon J.-J., Hoffmann R., Boigegrain R., Brodin R., Kan J.-P., Soubrie P., Bio. Med. Chem. Lett., 2, 833-838 (1992); Kan J. P., Steinberg R., Oury-Donat F., Michaud J. C., Thurneyssen O., Terranova J. P., Gueudet C., Souilhac J., Brodin R., Boigegrain R., Wermuth C. G., Worms P., Soubrie P., Fur G. L., Psychopharmacology, 112, 219-227 (1993).
8. Wermuth C. G., Bourguignon J.-J., Hoffmann R., Boigegrain R., Brodin R., Kan J.-P., Soubrie P., Bio. Med. Chem. Lett., 2, 833-838 (1992); Kan J. P., Steinberg R., Oury-Donat F., Michaud J. C., Thurneyssen O., Terranova J. P., Gueudet C., Souilhac J., Brodin R., Boigegrain R., Wermuth C. G., Worms P., Soubrie P., Fur G. L., Psychopharmacology, 112, 219-227 (1993).
9. Messer W. S., Jr., Bohnett M. S., Stibbe J., Neurosci. Lett., 116, 184-189 (1990).
10. Suzuki T., Toshinao U., Mitsuru O., Tunemasa S., Kataoka T., Chem. Pharm. Bull., 46, 1265-1273 (1998).
11. Miyano S., Mibu N., Irie M., Fujii S., Fujisaka F., Abe N., Sumoto K., J. Chem. Soc., Perkin Trans. 1, 1987, 313-316; Miyano S., Irie M., Mibu N., Miyamoto Y., Nagata K., Sumoto K., J. Chem. Soc., Perkin Trans. 1, 1988, 1057-1063.
12. Miyano S., Mibu N., Irie M., Fujii S., Fujisaka F., Abe N., Sumoto K., J. Chem. Soc., Perkin Trans. 1, 1987, 313-316; Miyano S., Irie M., Mibu N., Miyamoto Y., Nagata K., Sumoto K., J. Chem. Soc., Perkin Trans. 1, 1988, 1057-1063.
13. Flynn D. D., Mash D. C., J. Pharmacol. Exp. Ther., 250, 573-581 (1989).
14. Yamamura H. I., Snyder S. H., Proc Natl. Acad. U. S. A., 71, 1725-1729 (1974).
15. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
16. Banker G. A., Cowan W. M., Brain Res., 126, 397-402 (1977).
17. Lenox R. H., Hendly D., Ellis J., J. Neurochem., 50, 558-564 (1988).